- Record: found
- Abstract: not found
- Article: not found
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins ,
Elizabeth R Plimack ,
Igor Puzanov ,
Mayer N Fishman ,
David F McDermott ,
Daniel C Cho ,
Ulka Vaishampayan ,
Saby George ,
Thomas E Olencki ,
Jamal C Tarazi ,
Brad Rosbrook ,
Kathrine C Fernandez ,
Mariajose Lechuga ,
Toni K Choueiri
March 2018
March 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors
of the VEGF pathway have been characterised by excess toxicity, precluding further
development. We hypothesised that axitinib, a more selective VEGF inhibitor than others
previously tested, could be combined safely with pembrolizumab (anti-PD-1) and yield
antitumour activity in patients with treatment-naive advanced renal cell carcinoma.